Have a regulatory question?
Talk to a Korea regulatory specialist about your device, your timeline, or your next submission.
Talk to a specialist
ERP runs the business; MES runs the production floor. The conflation costs medical device manufacturers in audit findings and traceability gaps. A side-by-side comparison.
This document is not yet available for download. Please contact us if you need it urgently.
No previous versions available.
Medical device manufacturers routinely deploy a single enterprise system — typically an ERP — and attempt to use it for both business operations (orders, inventory, finance) and production floor management (work orders, batch records, in-process inspection). The ERP can be configured to handle some production data, but the configuration consistently breaks down at three audit-relevant points:
Electronic Device History Record (eDHR) granularity. ERPs typically capture order-level and shipment-level data. eDHRs need step-level data with operator identification per step.
Real-time process parameter capture. Manufacturing process validation requires capturing actual process parameters (temperature, pressure, time) per unit, often at multiple points per unit. ERPs capture aggregate batch data, not per-unit telemetry.
In-process non-conformance routing. When a unit fails an in-process inspection on the floor, the non-conformance must route to disposition in real time. ERPs typically batch non-conformances for QA review hours or days later.
These gaps are not theoretical. They are routine findings in MDSAP, KGMP, and FDA inspections.
For clarity, the value of ERP in a medical device manufacturing business is real and substantial. ERPs handle:
For these activities, ERP is the right system and a well-deployed ERP carries significant operational benefit.
The question is not "ERP or MES" — it is "what specifically does each system do, and how do they integrate?"
An MES is purpose-built for the production floor. Its core capabilities:
The MES captures, for every produced unit:
The eDHR is the per-unit manufacturing record. For ISO 13485, FDA 21 CFR 820, and KGMP, this record must be retrievable for the device's full retention period (typically 10+ years post-EOL).
The MES displays the latest-approved work instructions to the operator at the moment they perform the work. Critical properties:
ERPs cannot do this. They can hold work order metadata, but they cannot deliver step-level work instructions with real-time approval status.
MES enforces inspection at the points and frequencies defined by the manufacturing process validation:
For every shipped serial number, MES can produce the full traceability trace within minutes:
ERPs can produce batch-level genealogy but not unit-level genealogy in the depth required for KGMP/FDA inspection.
A correctly architected MES + ERP stack has clear data flows:
ERP ──────► MES
(work orders, materials availability, customer order priority)
MES ──────► ERP
(production completion, materials consumption, scrap, finished goods receipt)
PLM ──────► MES
(approved BOM, current work instructions, specifications)
MES ──────► eQMS
(non-conformances, in-process trend data, eDHR for review)
eQMS ──────► MES
(CAPA-driven work instruction updates via PLM)
The systems are distinct but tightly integrated. None of them is a "system of record" for everything; each is the system of record for what it does well.
A common objection to MES deployment: cost. The comparison is not as one-sided as it appears.
ERP-only with manual eDHR (typical starting state):
ERP + MES:
The crossover point — where ERP+MES becomes cheaper than ERP-only — depends on production volume, audit frequency, and product complexity. For mid-size medical device manufacturers producing more than 10,000 units/year of Class II products, the crossover is typically in year 2–3 post-MES deployment.
MES deployment is not the right answer in every situation. It is premature when:
The right sequence is generally: QMS → PLM → MES. Skipping ahead causes integration pain.
Conversely, three signals suggest MES is overdue:
For manufacturers building or extending Korean manufacturing operations, MES selection has specific KGMP considerations:
A note: MES depends on PLM for current work instructions and BOM. A weak PLM upstream means MES inherits stale or inconsistent work instructions. Many MES deployments stall not because of MES issues but because the upstream PLM cannot deliver authoritative content. Manufacturers planning MES deployment should evaluate PLM readiness first.
The Platform MES service runs MES platform selection and deployment for medical device manufacturers. The upstream Platform PLM work establishes the design source-of-truth that feeds MES. For the full eQMS infrastructure that integrates MES, PLM, and quality records, Platform eQMS and the eQMS service together cover the stack. For Korean manufacturing specifically, the platform work integrates with Korea QMS Foundation.
Talk to a Korea regulatory specialist about your device, your timeline, or your next submission.
Talk to a specialist
Annex II/III for MDR, Annex I/II for IVDR. GSPR checklists, Notified Body engagement, and the Korean cross-reference for manufacturers entering both regions.

Korea's UDI system runs on Korean GS1 codes and ties to the MFDS database. A practical implementation guide aligned with FDA UDI and EU MDR EUDAMED requirements.

MFDS approval gets your device into Korea; HIRA and NECA decide whether hospitals can afford to use it. A guide to navigating Korea's two-stage reimbursement system.